Innate Pharma S.A. (EPA: IPH)
France
· Delayed Price · Currency is EUR 2.090
-0.020 (-0.95%)
Aug 30, 2024, 5:35 PM CET
Innate Pharma Cash Flow Statement
Financials in millions EUR. Fiscal year is September - August.
Millions EUR. Fiscal year is Sep - Aug.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Feb '24 Feb 29, 2024 | Aug '23 Aug 31, 2023 | Aug '22 Aug 31, 2022 | Aug '21 Aug 31, 2021 | Aug '20 Aug 31, 2020 | Aug '19 Aug 31, 2019 | 2018 - 2014 |
| Net Income | 17.16 | 11.43 | 15.91 | 11.61 | 7.12 | 11.05 | Upgrade
|
| Depreciation & Amortization | 15.22 | 8.12 | 9.36 | 8.46 | 8.46 | 9.17 | Upgrade
|
| Other Amortization | 1.24 | 0.8 | - | - | - | - | Upgrade
|
| Loss (Gain) From Sale of Assets | 0.14 | 0.16 | -1.42 | -0.21 | -0.22 | 0.24 | Upgrade
|
| Asset Writedown & Restructuring Costs | 12.99 | 13 | - | -0.01 | -0.02 | 0.09 | Upgrade
|
| Loss (Gain) on Equity Investments | - | - | - | 4.85 | 4.51 | 0.42 | Upgrade
|
| Other Operating Activities | -0.07 | -1.13 | 0.89 | -0.73 | 1.36 | -0.4 | Upgrade
|
| Change in Accounts Receivable | -0.63 | -0.63 | -1.84 | - | - | - | Upgrade
|
| Change in Inventory | -12.76 | -12.76 | -12.21 | - | - | - | Upgrade
|
| Change in Accounts Payable | 7.8 | 7.8 | 3.7 | - | - | - | Upgrade
|
| Change in Other Net Operating Assets | -28.46 | 1.92 | 40.17 | 37.85 | 6.15 | 7.84 | Upgrade
|
| Operating Cash Flow | 12.61 | 28.71 | 54.56 | 61.81 | 27.36 | 28.4 | Upgrade
|
| Operating Cash Flow Growth | -62.91% | -47.39% | -11.72% | 125.95% | -3.69% | -16.88% | Upgrade
|
| Capital Expenditures | -8.72 | -9.6 | -8.21 | -10.56 | -14.31 | -13.22 | Upgrade
|
| Sale of Property, Plant & Equipment | 0.18 | 0.2 | 2.58 | 0.25 | 4.94 | 0.35 | Upgrade
|
| Cash Acquisitions | 0.2 | 0.2 | -5.83 | - | -0.4 | -4.15 | Upgrade
|
| Investment in Securities | - | - | 0 | 0.18 | 0.01 | - | Upgrade
|
| Other Investing Activities | -0 | -0 | - | -0 | -0 | - | Upgrade
|
| Investing Cash Flow | -8.34 | -9.19 | -11.46 | -10.13 | -9.76 | -17.02 | Upgrade
|
| Short-Term Debt Issued | - | 1.67 | 0.01 | 0.02 | - | - | Upgrade
|
| Long-Term Debt Issued | - | 1.68 | 14.89 | 2.69 | 8.36 | 10.3 | Upgrade
|
| Total Debt Issued | 7.1 | 3.35 | 14.9 | 2.71 | 8.36 | 10.3 | Upgrade
|
| Short-Term Debt Repaid | - | - | - | - | -0.01 | -0.11 | Upgrade
|
| Long-Term Debt Repaid | - | -8.65 | -20.12 | -10.37 | -7.75 | -10.79 | Upgrade
|
| Total Debt Repaid | -10.43 | -8.65 | -20.12 | -10.37 | -7.76 | -10.9 | Upgrade
|
| Net Debt Issued (Repaid) | -3.33 | -5.3 | -5.23 | -7.66 | 0.6 | -0.6 | Upgrade
|
| Issuance of Common Stock | - | - | 0.5 | - | 0.62 | - | Upgrade
|
| Repurchase of Common Stock | -4.51 | -4.51 | - | - | - | -0.78 | Upgrade
|
| Common Dividends Paid | -3.62 | -3.34 | -3.05 | -2.71 | -2.8 | -2.35 | Upgrade
|
| Other Financing Activities | -0.46 | -0.5 | 0.02 | - | -0 | - | Upgrade
|
| Financing Cash Flow | -11.92 | -13.65 | -7.76 | -10.37 | -1.59 | -3.74 | Upgrade
|
| Foreign Exchange Rate Adjustments | 0.02 | 0.02 | 0 | - | -0 | -0 | Upgrade
|
| Miscellaneous Cash Flow Adjustments | 0 | -0 | 0.1 | - | 0 | 0 | Upgrade
|
| Net Cash Flow | -7.63 | 5.88 | 35.45 | 41.31 | 16.01 | 7.65 | Upgrade
|
| Free Cash Flow | 3.89 | 19.11 | 46.36 | 51.25 | 13.05 | 15.19 | Upgrade
|
| Free Cash Flow Growth | -84.76% | -58.77% | -9.56% | 292.75% | -14.08% | -45.60% | Upgrade
|
| Free Cash Flow Margin | 1.17% | 6.87% | 20.94% | 25.13% | 7.48% | 7.27% | Upgrade
|
| Free Cash Flow Per Share | 2.33 | 11.47 | 27.82 | 30.74 | 7.83 | 9.12 | Upgrade
|
| Levered Free Cash Flow | 3.03 | 14.28 | 45.49 | 49.61 | 6.73 | 13.04 | Upgrade
|
| Unlevered Free Cash Flow | 3.76 | 14.73 | 46.07 | 50.07 | 7.29 | 13.74 | Upgrade
|
| Change in Net Working Capital | 34.04 | 5.6 | -28.74 | -37.52 | -5.41 | -4.81 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.